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1. INTRODUCTION {#edm25-sec-0005}
===============

Type 2 diabetes mellitus (T2DM) is a leading cause of chronic kidney disease (CKD) in the United States, with approximately 40% of diabetes patients having CKD.[1](#edm25-bib-0001){ref-type="ref"} Reduced renal function can complicate diabetes management resulting in an increased risk of adverse events, for example severe hypoglycaemia, or decreased efficacy. Although many newer diabetes medications have become available in the last decade, most have not been widely studied in CKD populations under routine care, leaving clinicians caring for these patients with little evidence regarding best practices, particularly in patients with more severe renal impairment. Among the recently marketed medications, linagliptin, a dipeptidyl peptidase 4 (DPP‐4) inhibitor, is the only agent in the United States that does not require dose adjustment in T2DM patients with renal impairment, suggesting it may be preferentially prescribed among these patients.

We sought to describe baseline kidney function and other key characteristics among T2DM patients initiating linagliptin and other diabetes medications and to explore prescribing patterns among T2DM patients with moderate to severe renal impairment before and after the launch of linagliptin.

2. METHODS {#edm25-sec-0006}
==========

Within a large U.S. commercial insurance data set (Clinformatics^™^ DataMart; OptumInsight, Eden, Prairie, MN, USA), we identified T2DM patients (ICD‐9 diagnosis250.x0 or250.x2) initiating linagliptin or other diabetes agents between 05/2011 (linagliptin launch) and 09/2015 (Table [1](#edm25-tbl-0001){ref-type="table"}), with no use of that agent in the previous 6 months. Patient characteristics were measured during the 6 months prior to treatment initiation, and for approximately 30% of the population, included baseline estimated glomerular filtration rate (eGFR)[2](#edm25-bib-0002){ref-type="ref"} and haemoglobin A1c (HbA1c). In a separate cohort of T2DM patients with moderate to severe renal impairment (ICD‐9 diagnosis code of CKD stage 3 or higher \[585.3x‐6x\]), patterns of diabetes therapy initiation before and after the launch of linagliptin (01/2006‐09/2015) were plotted by year for DPP‐4 inhibitors (by class and individual agents), metformin, 2nd generation sulphonylureas, GLP‐1 receptor agonists, glitazones, SGLT‐2 inhibitors, meglitinides and insulin.

###### 

Baseline characteristics of patients with a new diabetes treatment episode after the launch of linagliptin (May 2011‐Sep 2015)

  Characteristic                                                     Linagliptin     Other DPP4i     Metformin        2nd gen SU       GLP‐1 RA        Glitazones      SGLT2i          Glinides      Insulin
  ------------------------------------------------------------------ --------------- --------------- ---------------- ---------------- --------------- --------------- --------------- ------------- ---------------
  N                                                                  28 900          153 596         465 695          227 036          55 083          46 335          39 048          8695          150 088
  Age, mean (SD)                                                     60.2 (12.4)     61.8 (12.7)     59.8 (13.2)      62.2 (13.1)      56.2 (11.3)     62.6 (12.7)     56.4 (10.7)     66.9 (12.6)   62.5 (13.5)
  Females, N (%)                                                     12 562 (43.5)   69 861 (45.5)   220 873 (47.4)   100 900 (44.4)   29 099 (52.8)   19 487 (42.1)   16 722 (42.8)   4346 (50.0)   70 516 (47.0)
  Comorbidity index,[a](#edm25-note-0002){ref-type="fn"} mean (SD)   2.0 (1.6)       1.9 (1.5)       1.6 (1.3)        1.9 (1.6)        1.7 (1.2)       1.8 (1.5)       1.6 (1.1)       2.4 (1.9)     2.5 (2.1)
  Renal dysfunction, N (%)                                           6478 (22.4)     25 626 (16.7)   43 873 (9.4)     38 369 (16.9)    7376 (13.4)     8604 (18.6)     4010 (10.3)     2497(28.7)    40 582 (27.0)
  CKD, N (%)                                                         3734 (12.9)     13 234 (8.6)    18 292 (3.93)    19 344 (8.5)     3384 (6.1)      4685 (10.1)     1584 (4.06)     1454 (16.7)   20 260 (13.5)
  CKD stage, N (%)                                                                                                                                                                                   
  CKD stage 1                                                        174 (0.6)       817 (0.5)       1735 (0.4)       1115 (0.5)       284 (0.5)       295 (0.6)       226 (0.6)       42 (0.5)      830 (0.6)
  CKD stage 2                                                        395 (1.4)       2124 (1.4)      4658 (1.0)       2880 (1.3)       592 (1.1)       798 (1.7)       430 (1.1)       146 (1.7)     2325 (1.6)
  CKD stage 3                                                        2351 (8.1)      8391 (5.5)      10 935 (2.4)     12 092 (5.3)     2094 (3.8)      2998 (6.5)      872 (2.2)       866 (10.0)    11 420 (7.6)
  CKD stage 4                                                        584 (2.0)       1372 (0.9)      619 (0.1)        2159 (1.0)       324 (0.6)       456 (1.0)       43 (0.1)        270 (3.1)     3096 (2.1)
  CKD stage 5                                                        57 (0.2)        140 (0.1)       64 (0.0)         199 (0.1)        25 (0.1)        26 (0.1)        2 (0.0)         20 (0.2)      357 (0.2)
  End stage renal disease, N (%)                                     173 (0.6)       390 (0.3)       281 (0.1)        899 (0.4)        65 (0.1)        112 (0.2)       11 (0.0)        110 (1.3)     2232 (1.5)
  HbA1C %, mean (SD)                                                 8.3 (4.2)       8.4 (3.3)       7.9 (3.8)        8.6 (4.3)        8.6 (4.3)       8.5 (2.4)       8.8 (3.3)       8.3 (5.1)     9.4 (4.5)
  Patients with HbA1c available, N (%)                               9644 (33.4)     46 324 (30.2)   123 539 (26.5)   59 299 (26.1)    16 530 (30.0)   14 188 (30.6)   14 768 (37.8)   2697 (31.0)   35 339 (23.6)
  eGFR, mean (SD)                                                    88.8 (27.4)     92.7 (23.5)     97.0 (19.0)      91.43 (24.4)     96.87 (21.5)    90.6 (24.4)     100.7 (18.3)    82.1 (26.7)   86.70 (27.8)
  Patients with creatinine available, N (%)                          10 647 (36.8)   49 984 (32.5)   136 719 (29.4)   65 087 (28.7)    18 170 (33.0)   15 051 (32.5)   15 919 (40.8)   3028 (34.8)   41 146 (27.4)
  eGFR Category, N (%)                                                                                                                                                                               
  eGFR ≥90 mL/min per 1.73 m^2^                                      6242 (58.6)     30 396 (60.8)   91 471 (66.9)    38 078 (58.5)    13 008 (71.6)   8441 (56.1)     12 220 (76.8)   1289 (42.6)   21 823 (53.0)
  eGFR 60‐89 mL/min per 1.73 m^2^                                    2535 (23.8)     14 450 (28.9)   40 017 (29.3)    19 370 (29.8)    3865 (21.3)     4737 (31.5)     3238 (20.3)     1086 (35.9)   11 952 (29.1)
  eGFR \<60 mL/min per 1.73 m^2^                                     1870 (17.6)     5138 (10.3)     5231 (3.8)       7639 (11.7)      1297 (7.1)      1873 (12.4)     461 (2.9)       653 (21.6)    7371 (17.9)
  eGFR 45‐59 mL/min per 1.73 m^2^                                    883 (8.3)       2806 (5.6)      3755 (2.8)       3940 (6.1)       731 (4.0)       1003 (6.7)      332 (2.1)       310(10.2)     3135 (7.6)
  eGFR 30‐44 mL/min per 1.73 m^2^                                    644 (6.1)       1637 (3.3)      1161 (0.9)       2464 (3.8)       411 (2.3)       617 (4.1)       101 (0.6)       204 (6.7)     2381 (5.8)
  eGFR 15‐29 mL/min per 1.73 m^2^                                    288 (2.7)       573 (1.2)       245 (0.2)        1020 (1.6)       135 (0.7)       223 (1.5)       24 (0.2)        107 (3.5)     1389 (3.4)
  eGFR \<15 mL/min per 1.73 m^2^                                     55 (0.5)        122 (0.2)       70 (0.1)         215 (0.3)        20 (0.1)        30 (0.2)        4 (0.0)         32 (1.1)      466 (1.1)

Other DPP‐4i, other DPP‐4 inhibitors (i.e alogliptin, saxagliptin and sitagliptin); 2nd gen SU, 2nd generation sulphonylureas (i.e glipizide, glimepiride, glyburide); GLP‐1 RA, GLP‐1 receptor agonists (i.e albiglutide, dulaglutide, exenatide, liraglutide); glitazones, thiazolidinediones (i.e rosiglitazone, pioglitazone); glinides, meglitinides (i.e nateglinide, repaglinide); SGLT2i, SGLT‐2 inhibitors (i.e canagliflozin, dapagliflozin, empagliflozin); SD, standard deviation; CKD, chronic kidney disease, assessed through ICD‐9 diagnosis codes; HbA1c, haemoglobin A1c; eGFR, estimated glomerular filtration rate.

As measured by the Romano modification of the Charlson comorbidity score.[4](#edm25-bib-0004){ref-type="ref"}
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3. RESULTS {#edm25-sec-0007}
==========

Of 1 174 476 T2DM patients initiating a diabetes medication between 05/2011 and 09/2015, 28 900 (2.5%) were linagliptin initiators. The proportion of baseline kidney disease (overall kidney dysfunction, any stage of CKD,[3](#edm25-bib-0003){ref-type="ref"} respectively) was higher among patients initiating linagliptin (22.4%, 12.9%), meglitinides (28.7%, 16.7%) or insulin (27.0%, 13.5%), resulting in a higher burden of comorbidities[4](#edm25-bib-0004){ref-type="ref"} compared to patients initiating other diabetes medications. In particular, patients initiating linagliptin, meglitinides or insulin had higher proportions of baseline CKD stage 3 or higher or eGFR \<60 mL/min per 1.73 m^2^ (Table [1](#edm25-tbl-0001){ref-type="table"}).

When assessing the prescribing patterns among T2DM patients with moderate to severe renal impairment between 01/2006 and 09/2015 (N = 100 847), initiation of DPP‐4 inhibitors, metformin and SGLT‐2 inhibitors increased over time, whereas initiation of sulphonylureas, glitazones, meglitinides and insulin decreased (Figure [1](#edm25-fig-0001){ref-type="fig"}). After its launch, linagliptin use among T2DM patients with moderate to severe renal impairment increased over time, whereas the use of other DPP‐4 inhibitors either decreased (sitagliptin and saxagliptin) or remained stable (alogliptin) (Figure [1](#edm25-fig-0001){ref-type="fig"}). Secondary analyses restricted to patients with baseline eGFR \<60 mL/min per 1.73 m^2^ confirmed observed utilization trends.

![Utilization trends before and after the launch of linagliptin among patients with moderate to severe renal impairment (CKD Stage 3 or higher) initiating a glucose‐lowering drug. Other DPP‐4i, other DPP‐4 inhibitors (ie, alogliptin, saxagliptin and sitagliptin); 2nd gen SU, 2nd generation sulphonylureas (ie, glipizide, glimepiride, glyburide); GLP‐1 RA,GLP‐1 receptor agonists (ie, albiglutide, dulaglutide, exenatide, liraglutide); glitazones, thiazolidinediones (ie, rosiglitazone, pioglitazone); glinides, meglitinides (ie, nateglinide, repaglinide); SGLT2i, SGLT‐2 inhibitors (ie, canagliflozin, dapagliflozin, empagliflozin); SD, standard deviation; CKD, chronic kidney disease, assessed through ICD‐9 diagnosis codes; HbA1c, haemoglobin A1c; eGFR, estimated glomerular filtration rate. ^1^As measured by the Romano modification of the Charlson comorbidity score[4](#edm25-bib-0004){ref-type="ref"}](EDM2-1-e00005-g001){#edm25-fig-0001}

4. DISCUSSION {#edm25-sec-0008}
=============

Among patients initiating newer diabetes medications, those initiating linagliptin had the highest prevalence of moderate to severe renal impairment, suggesting preferential prescribing in routine care. These patterns should be accounted for in the design of noninterventional studies related to linagliptin. Despite the increase in linagliptin use, insulin, sulphonylureas, metformin and other DPP‐4 inhibitors, that is sitagliptin, remain the most frequently chosen agents among T2DM patients with moderate to severe renal impairment. While the choice of traditional antidiabetic agents that is insulin, short‐acting sulphonylureas and meglitinides is acknowledged,[5](#edm25-bib-0005){ref-type="ref"} and the increasing role of metformin has been previously observed,[6](#edm25-bib-0006){ref-type="ref"}, [7](#edm25-bib-0007){ref-type="ref"} the prominent role of DPP‐4 inhibitors among T2DM patients with kidney disease in recent years has been largely undocumented. Such extensive use in clinical practice is unforeseen, as the data on the effects of DPP‐4 inhibitors in patients with diabetes and kidney dysfunction in routine care are limited, and current guidelines do not specifically recommend the preferential use of these agents over alternative treatments in this population.[5](#edm25-bib-0005){ref-type="ref"}, [8](#edm25-bib-0008){ref-type="ref"} In the light of this, further investigation of the safety and effectiveness of DPP‐4 inhibitors in the routine care of T2DM patients with renal impairment is sorely needed to either corroborate or discourage current prescribing patterns.
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